Siemens Showcases Broad Portfolio of Integrated IVD Solutions at EUROMEDLAB Munich
|
By LabMedica International staff writers Posted on 11 Apr 2022 |

Siemens Healthineers (Erlangen, Germany) showcased its broad portfolio of integrated IVD solutions at EUROMEDLAB 2022 which was held 10th-14th April 2022 in Munich, Germany.
At EUROMEDLAB Munich, Siemens demonstrated it automation solutions for labs of all sizes that are fully scalable, innovative, and customized for individual workflows. Siemens demonstrated how labs could achieve open, one-touch, end-to-end testing with its Aptio Automation solution and drive open, one-touch sample preparation for multidisciplinary labs with its Atellica Task Targeted Automation solution. The company also demonstrated how its Atellica Integrated Automation solution could streamline the biggest chemistry and immunoassay workloads for laboratories.
The company showcased its two new high-volume hematology analyzers - Atellica HEMA 570 and 580 - designed to meet the hematology testing needs of today’s high-volume labs. Sharing fast throughput and an identical footprint, both instruments are intended to pair with advanced informatics and automation solutions to suit diverse workflow requirements and drive efficiencies across labs and networks. Each delivers a range of analytical capabilities, including an 8-part white blood cell differential, with the Atellica HEMA 580 Analyzer offering an expanded menu complete with optical platelet and reticulocyte testing. In addition, Siemens highlighted its epoc Blood Analysis System with epoc NXS Hos, the market-first Android powered patient-side testing solution. epoc is a handheld, wireless solution to enable comprehensive blood analysis testing at the patient’s side on a single room temperature test card, with results in less than a minute.
Siemens also displayed the Dimension EXL 200 Integrated Chemistry System which can simplify operations with an integrated chemistry and immunoassay analyzer in a compact footprint. Also on display were the Sysmex CN-3000 and CN-6000 fully automated, mid- and high-volume coagulation analyzers that are designed to tackle big lab challenges. In addition, Siemens exhibited the new Atellica DCA connected, scalable, and portable analyzer that can collect actionable HbA1c and ACR results in minutes, alongside the Atellica CI 1900 System which is being developed for lower- to mid-volume laboratories. Among its high-performing assays, Siemens showcased the breadth and depth of its clinical menu from cardiac and allergy testing to dedicated plasma protein/FLC to real-time PCR testing for SARS-CoV-2, new preeclampsia markers and more.
Related Links:
Siemens Healthineers
Latest EUROMEDLAB 2022 News
- Sebia Displays Automated, High Throughput Capillary Electrophoresis (CE) Instruments at EUROMEDLAB 2022
- Snibe Showcases Maglumi X3 Fully Automatic CLIA System at EUROMEDLAB 2022
- Thermo Fisher Presents Cascadion SM Clinical Analyzer and LC-MS IVD Medical Devices at EUROMEDLAB 2022
- Binding Site Exhibits Special Protein Analyzer Optilite at EUROMEDLAB 2022
- DIRUI Presents High-End Diagnostic Systems for Hospitals and High-Volume Labs at EUROMEDLAB 2022
- DIESSE Diagnostica Demonstrates Advanced Immunoassay and ESR Analyzers at EUROMEDLAB 2022
- Gentian Diagnostics Exhibits Assays for Wide Range of Clinical Chemistry Platforms at EUROMEDLAB
- Ortho Presents Broad Menu of High-Performing Assays at EUROMEDLAB 2022
- Technopath Highlights Laboratory Solutions to Enhance QC Efficiencies at EUROMEDLAB 2022
- Mindray Demonstrates Latest IVD Innovations at EUROMEDLAB 2022
- LumiraDx Presents LumiraDx Point of Care Instrument at IFCC EUROMEDLAB
- Beckman Coulter Presents Virtual Showcase of Laboratory Solutions at EUROMEDLAB 2022
- Horiba Showcases Latest Hematology and Hemostasis Solutions at EUROMEDLAB 2022
- Sysmex Europe Exhibits New Products and Innovative Concepts in Infection Diagnostics at EUROMEDLAB 2022
- Roche Showcases the Future of Diagnostic Solutions at EUROMEDLAB 2022
- EUROMEDLAB 2022 Showcases Breakthrough Technologies and Cutting Edge Scientific Advances in Clinical Lab Diagnostics
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








